Clinical trials: Post Operative Nausea and Vomiting
- Condition Post Operative Nausea and Vomiting
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Post-operative Nausea and Vomiting
Mass-balance Study of [14C]-APD421 in Healthy Volunteers
Open-label, non-randomised, single dose study in 6 healthy male subjects to assess the mass balance recovery, metabolite profile, metabolite identification and pharmacokinetics of 14C-labelled APD421
- Trial name
- NCT02881840
- Testing
- 14C-APD421
- Where
- Netherlands
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Acacia Pharma Ltd
Post-Operative Nausea and Vomiting (PONV)
Single Dose Safety Study for Compound to Treat Post-Operative Nausea and Vomiting (PONV)
The purpose of this study is to describe the safety and tolerability and pharmacokinetics of a single intravenous administration of the new, Sulfobutyl Ether-7-Beta-Cyclodextrin (Captisol™) based, formulation in Healthy Adult…
- Trial name
- NCT01290133
- Testing
- GW597599
- Where
- Australia
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Accenture
Postoperative Nausea and Vomiting
Study of APD421 With and Without Ondansetron
Collection of pharmacokinetic and electrocardiograph data from healthy volunteers given APD421 +/- ondansetron
- Trial name
- NCT03583489
- Testing
- APD421, Ondansetron
- Where
- United Kingdom
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Acacia Pharma Ltd
Postoperative Nausea and Vomiting
Efficacy and Safety Study of Aprepitant Injection for Prevention of Post-operative Nausea and Vomiting
The goal of this Interventional study is to evaluate the efficacy and safety of Aprepitant Injection(QLG2174) for preventing PONV in Chinese patients.
- Trial name
- NCT06932107
- Testing
- Aprepitant Injection
- Where
- China
- Volunteers
- 518 people, healthy volunteers welcome
- Sponsor
- Qilu Pharmaceutical (Hainan) Co., Ltd.
Chemotherapy-Induced Nausea and Vomiting (CINV), Radiotherapy-induced Nausea and Vomiting (RINV)
A Study to Compare the Bioavailability of Ondansetron Following Nasal (NS003) and IV Administration in Healthy Adults
A Study to Compare the Bioavailability of Ondansetron Following Nasal (NS003) and IV Administration in Healthy Adults
- Conditions
- Chemotherapy-Induced Nausea and Vomiting (CINV), Radiotherapy-induced Nausea and Vomiting (RINV), Postoperative Nausea and Vomiting
- Trial name
- NCT07868861
- Testing
- NS003 Ondansetron HCl microspheres powder for nasal application, Ondansetron Solution for IV infusion 8mg
- Where
- Israel
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Nasus Pharma
Chemotherapy-Induced Nausea and Vomiting, Postoperative Nausea and Vomiting
A Study to Investigate the Safety and Tolerability of MK-0517 in Healthy Subjects (MK-0517-012)
This 5-part study will evaluate the safety, tolerability, and pharmacokinetics of two formulations of MK-0517 (with and without polysorbate 80) and aprepitant in healthy adults.
- Trial name
- NCT00990821
- Testing
- 90 mg MK-0517 (PS80), 100 mg MK-0517 (PS80), 100 MK-0517 (PS80) + 2 mg midazolam
- Volunteers
- 188 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Nausea and Vomiting, Postoperative, Nausea With Vomiting Chemotherapy-Induced
Crossover Study Comparing Ondansetron Orally Dissolving Film Strip (ODFS) With Zofran Orally Disintegrating Tablets
This was an open-label, balanced, two-treatment, two-period, randomized sequence crossover bioequivalence study with a 7-day washout between periods. Each treatment was administered after an overnight (10 hours) fast.
- Trial name
- 01905/08-09 (NCT01217190)
- Testing
- Ondansetron (ODFS), Zofran (ODT)
- Where
- India
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- MonoSol Rx
Postoperative Nausea and Vomiting
Phase I PK and Safety Study of Ondansetron Inhalation Powder
The goal of this clinical trial is to learn if LPI-1503 (Ondansetron Inhalation Powder) can deliver ondansetron into blood through inhalation. It will also learn about the safety of LPI-1503.
- Trial name
- NCT07498751
- Testing
- LPI-1503, IV Ondansetron, Oral Ondansetron
- Where
- Canada
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Luxena Pharmaceuticals, Inc.